Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Freeman

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Global Change Biology|October 20, 2021
Systematic over-crediting in California's forest carbon offsets programGrayson Badgley, Jeremy Freeman, Joseph J Hamman, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|August 16, 2014
Current management of papillary thyroid microcarcinoma in CanadaMazin Merdad, Antoine Eskander, John De Almeida, et al.
Journal of Clinical and Translational Hepatology|September 11, 2015
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to ClinicHenrik Andersen, Jeff Meyer, Jeremy Freeman, et al.
Journal of Eating Disorders|December 9, 2020
ANZAED practice and training standards for mental health professionals providing eating disorder treatmentKim Hurst, Gabriella Heruc, Chris Thornton, et al.
Thyroid : Official Journal of the American Thyroid Association|October 11, 2018
Summary of the Third World Congress on Thyroid CancerBryan McIver, Jeremy Freeman, Jatin P Shah, et al.
Journal of Clinical Pharmacology|July 22, 2014
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variablesMatthew Hruska, Xiaodong Wang, Phyllis Chan, et al.
Journal of Clinical Pharmacology|July 22, 2014
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response ratesXiaodong Wang, Matthew Hruska, Phyllis Chan, et al.
The Laryngoscope|April 8, 2014
Volume-outcome relationships for head and neck cancer surgery in a universal health care systemAntoine Eskander, Jonathan Irish, Patti A Groome, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|December 11, 2014
Overview of major salivary gland cancer surgery in Ontario (2003-2010)Antoine Eskander, Jonathan Irish, Jeremy Freeman, et al.
Head & Neck|June 5, 2015
Overview of surgery for oral cavity cancer in OntarioAntoine Eskander, Jonathan Irish, Patrick Gullane, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Global Change Biology|October 20, 2021
Systematic over-crediting in California's forest carbon offsets programGrayson Badgley, Jeremy Freeman, Joseph J Hamman, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|August 16, 2014
Current management of papillary thyroid microcarcinoma in CanadaMazin Merdad, Antoine Eskander, John De Almeida, et al.
Journal of Clinical and Translational Hepatology|September 11, 2015
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to ClinicHenrik Andersen, Jeff Meyer, Jeremy Freeman, et al.
Journal of Eating Disorders|December 9, 2020
ANZAED practice and training standards for mental health professionals providing eating disorder treatmentKim Hurst, Gabriella Heruc, Chris Thornton, et al.
Thyroid : Official Journal of the American Thyroid Association|October 11, 2018
Summary of the Third World Congress on Thyroid CancerBryan McIver, Jeremy Freeman, Jatin P Shah, et al.
Journal of Clinical Pharmacology|July 22, 2014
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variablesMatthew Hruska, Xiaodong Wang, Phyllis Chan, et al.
Journal of Clinical Pharmacology|July 22, 2014
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response ratesXiaodong Wang, Matthew Hruska, Phyllis Chan, et al.
The Laryngoscope|April 8, 2014
Volume-outcome relationships for head and neck cancer surgery in a universal health care systemAntoine Eskander, Jonathan Irish, Patti A Groome, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|December 11, 2014
Overview of major salivary gland cancer surgery in Ontario (2003-2010)Antoine Eskander, Jonathan Irish, Jeremy Freeman, et al.
Head & Neck|June 5, 2015
Overview of surgery for oral cavity cancer in OntarioAntoine Eskander, Jonathan Irish, Patrick Gullane, et al.
Pageof 9